A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).

Trial Details

NCT ID
NCT07281976
Phase
PHASE1 / PHASE2
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • LBL-024 for Injection
  • albumin-bound Paclitaxel injection
  • Toripalimab Injection
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Harbin, Heilongjiang, China|45.75,126.65
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the…
  • At the time of signing the informed consent form, the age was ≥ 18 years old.
  • The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
  • The expected survival time is at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →